Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$747,000Cash on Hand
1.8mo Cash Runway
Follow CDT by emailGet an email when CDT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CDT, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Shareholder vote Prospectus supplement registers resale of 33,649 shares by selling stockholders, attaching the Q3 2026 10-Q. Company effected a 1-for-20 reverse stock split effective November 5, 2026. Last sale price was $0.38 on November 16, 2026. Form 424B3 · SEC filing
Nov 16, 2026 ·
Shareholder vote Reported a 1-for-20 reverse stock split effective November 5, 2026, and registered 33,649 shares for resale by selling stockholders, mostly issued to J.J. Astor & Co., Sarborg Limited and service providers. The company will not receive proceeds from these resales. Form 424B3 · SEC filing
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Shareholder vote Stockholders approved three proposals at a November 12, 2026 special meeting: share issuances to J.J. Astor & Co. Form 8-K · SEC filing
Nov 9, 2026 ·
Deal Former CEO Dr. Andrew Regan, writing for Corvus Capital Limited, said Corvus intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share, absent a Board proposal. Form 8-K · SEC filing
Nov 9, 2026 ·
Deal Prospectus supplement registers resale of 33,649 shares by selling stockholders, with the company receiving no proceeds. It attaches an 8-K disclosing that Dr. Andrew Regan, former CEO and a significant stockholder, intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share. Form 424B3 · SEC filing
Nov 4, 2026 ·
Listing CDT Equity filed a certificate of amendment on Nov 2, 2026 for a 1-for-20 reverse stock split, effective Nov 5 at 5:00 p.m. ET, with Nasdaq trading on a split-adjusted basis from Nov 6 under CDT. Shares outstanding drop from 20,357,283 to about 1,017,864. Form 8-K · SEC filing
Nov 4, 2026 ·
Shareholder vote Prospectus supplement attaches an 8-K saying the board approved a 1-for-20 reverse stock split, effective November 5, 2026, cutting outstanding shares from 20,357,283 to about 1,017,864. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
CDT holds $747,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $1.2M/quarter from operations,
an estimated runway of 1.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:77 · High
Cash runway 2 months +40
ATM program on file since Apr 2026 +15
Shelf registration (S-3, Oct 2024) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for at least the next 12 months from the financial statement filing date.10-Q, Nov 2026
Share count +17% in a year +7
Raised after last reported balance sheet (Oct 2026) -10
Share count 1,900,144 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CDT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CDT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.